Candidacidal activity of selected ceragenins and human cathelicidin LL-37 in experimental settings mimicking infection sites

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Durnaœ, Bonita ^a,b   Wnorowska, Urszula ^c   Pogoda, Katarzyna ^d   Deptuła, Piotr ^c   Wa tek, Marzena ^b   Piktel, Ewelina ^c   Głuszek, Stanisław ^a   Gu, Xiaobo ^e   Savage, Paul B ^e   Niemirowicz, Katarzyna ^c   Bucki, Robert ^a,c  

^a JAN KOCHANOWSKI UNIVERSITY   (Poland)

^b Center Holy Cross Regional Hospital   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^e Brigham Young University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CERAGENIN CATIONIC STEROID ANTIBIOTIC 13; CERAGENIN CATIONIC STEROID ANTIBIOTIC 131; CERAGENIN CATIONIC STEROID ANTIBIOTIC 192; DEOXYRIBONUCLEASE I; FLUCONAZOLE; OMIGANAN; PLACEBO; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CERAGENIN CSA-13; STEROID;

AFFINITY LABELING; ARTICLE; ASPERGILLUS FUMIGATUS; BIOFILM; BODY FLUID; CANDIDA; CELL PROLIFERATION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG STRUCTURE; FUNGAL CELL; FUNGAL MEMBRANE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HUMAN; LIPOPHILICITY; MEMBRANE DAMAGE; MICROSCOPY; MYCOSIS; NONHUMAN; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANTIMICROBIAL CATIONIC PEPTIDES; ASPERGILLUS FUMIGATUS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; STEROIDS;

EID: 84976509252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157242     Document Type: Article

References (64)

1. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014; 20(7):1149-55. doi: 10.3201/ eid2007.140087 PMID: 24960557; PubMed Central PMCID: PMCPMC4073874.
2. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012; 36(2):288-305. doi: 10.1111/j.1574-6976.2011.00278.x PMID: 21569057.
3. Polke M, Hube B, Jacobsen ID. Candida survival strategies. Adv Appl Microbiol. 2015; 91:139-235. doi: 10.1016/bs.aambs.2014.12.002 PMID: 25911234.
4. Singh S, Fatima Z, Hameed S. Predisposing factors endorsing Candida infections. Infez Med. 2015; 23 (3):211-23. PMID: 26397289.
5. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends in microbiology. 2001; 9 (7):327-35. PMID: 11435107.
6. Ganguly S, Mitchell AP. Mucosal biofilms of Candida albicans. Curr Opin Microbiol. 2011; 14(4):380-5. doi: 10.1016/j.mib.2011.06.001 PMID: 21741878; PubMed Central PMCID: PMCPMC3159763.
7. Harriott MM, Noverr MC. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol. 2011; 19(11):557-63. doi: 10.1016/j.tim.2011.07.004 PMID: 21855346; PubMed Central PMCID: PMCPMC3205277.
8. Ramage G, Vandewalle K, Wickes BL, López-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001; 18(4):163-70. PMID: 15496122.
9. Mathé L, Van Dijck P. Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet. 2013; 59(4):251-64. doi: 10.1007/s00294-013-0400-3 PMID: 23974350; PubMed Central PMCID: PMCPMC3824241.
10. Taff HT, Mitchell KF, Edward JA, Andes DR. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 2013; 8(10):1325-37. doi: 10.2217/fmb.13.101 PMID: 24059922; PubMed Central PMCID: PMCPMC3859465.
11. Chen L, Wen YM. The role of bacterial biofilm in persistent infections and control strategies. Int J Oral Sci. 2011; 3(2):66-73. doi: 10.4248/IJOS11022 PMID: 21485310; PubMed Central PMCID: PMCPMC3469879.
12. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010; 8(9):623-33. doi: 10.1038/ nrmicro2415 PMID: 20676145.
13. Steinberger RE, Holden PA. Extracellular DNA in single- and multiple-species unsaturated biofilms. Appl Environ Microbiol. 2005; 71(9):5404-10. doi: 10.1128/AEM.71.9.5404-5410.2005 PMID: 16151131; PubMed Central PMCID: PMCPMC1214645.
14. Sapaar B, Nur A, Hirota K, Yumoto H, Murakami K, Amoh T, et al. Effects of extracellular DNA from Candida albicans and pneumonia-related pathogens on Candida biofilm formation and hyphal transformation. J Appl Microbiol. 2014; 116(6):1531-42. doi: 10.1111/jam.12483 24661775 PMID: 24661775
15. Tetz GV, Artemenko NK, Tetz VV. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother. 2009; 53(3):1204-9. doi: 10.1128/AAC.00471-08 PMID: 19064900; PubMed Central PMCID: PMCPMC2650517.
16. Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol. 2012; 12(5):545-50. doi: 10.1016/j.coph.2012.06.006 PMID: 22776251; PubMed Central PMCID: PMCPMC3466353.
17. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol. 2010; 87(1):79-92. doi: 10.1189/jlb.0609382 PMID: 19808939.
18. Bucki R, Leszczyñska K, Namiot A, Sokoowski W. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp (Warsz). 2010; 58(1):15-25. doi: 10.1007/s00005-009-0057-2 PMID: 20049649.
19. Moncla BJ, Pryke K, Rohan LC, Graebing PW. Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv Biosci Biotechnol. 2011; 2(6):404-8. doi: 10.4236/abb.2011. 26059 PMID: 22611520; PubMed Central PMCID: PMCPMC3354962.
20. Aoki W, Ueda M. Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics. Pharmaceuticals (Basel). 2013; 6(8):1055-81. doi: 10.3390/ph6081055 PMID: 24276381; PubMed Central PMCID: PMCPMC3817730.
21. Savage PB, Li C, Taotafa U, Ding B, Guan Q. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett. 2002; 217(1):1-7. PMID: 12445638.
22. Epand RF, Savage PB, Epand RM. Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (Ceragenins). Biochim Biophys Acta. 2007; 1768(10):2500-9. doi: 10.1016/j. bbamem.2007.05.023 PMID: 17599802.
23. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother. 2010; 54(9):3708-13. doi: 10.1128/AAC.00380-10 PMID: 20585129; PubMed Central PMCID: PMCPMC2934994.
24. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51(4):1268-73. PMID: 17210765.
25. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother. 2008; 61(2):365-70. PMID: 18079128.
26. Leszczynska K, Namiot D, Byfield FJ, Cruz K, Zendzian-Piotrowska M, Fein DE, et al. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J Antimicrob Chemother. 2013; 68(3):610-8. doi: 10.1093/jac/dks434 PMID: 23134677; PubMed Central PMCID: PMCPMC3566669.
27. Lara D, Feng Y, Bader J, Savage PB, Maldonado RA. Anti-trypanosomatid activity of ceragenins. J Parasitol. 2010; 96(3):638-42. doi: 10.1645/GE-2329.1 PMID: 19958044; PubMed Central PMCID: PMCPMC2891312.
28. Howell MD, Streib JE, Kim BE, Lesley LJ, Dunlap AP, Geng D, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol. 2009; 129(11):2668-75. Epub 2009/06/12. doi: jid2009120 [pii] doi: 10.1038/jid.2009.120 PMID: 19516269.
29. Vila-Farrés X, Callarisa AE, Gu X, Savage PB, Giralt E, Vila J. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents. 2015; 46(5):568-71. doi: 10.1016/j.ijantimicag.2015.08.003 PMID: 26395218.
30. Isaacson RE. MBI-226. Micrologix/Fujisawa. Curr Opin Investig Drugs. 2003; 4(8):999-1003. PMID: 14508884.
31. Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother. 2004; 48(8):3112-8. doi: 10.1128/AAC.48.8.3112-3118. 2004 PMID: 15273128; PubMed Central PMCID: PMCPMC478492.
32. A service of the U.S. National Institutes of Health. Available: https://clinicaltrials.gov/.
33. Ding B, Guan Q, Walsh JP, Boswell JS, Winter TW, Winter ES, et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem. 2002; 45(3):663-9. PMID: 11806717.
34. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed. CLSI document M27-A3.2008.
35. Choi JH, Kang SR, Kim H, Um SH, Shin K, Choi JW, et al. Dye-doped silica nanoparticle with HIV-1 TAT peptide for bioimaging. J Biomed Nanotechnol. 2013; 9(2):291-4. PMID: 23627057.
36. Lv Y, Wang J, Gao H, Wang Z, Dong N, Ma Q, et al. Antimicrobial properties and membrane-active mechanism of a potential α-helical antimicrobial derived from cathelicidin PMAP-36. PLoS One. 2014; 9(1):e86364. doi: 10.1371/journal.pone.0086364 PMID: 24466055; PubMed Central PMCID: PMCPMC3897731.
37. Bucki R, Niemirowicz K, Wnorowska U, Watek M, Byfield FJ, Cruz K, et al. Polyelectrolyte-mediated increase of biofilm mass formation. BMC microbiology. 2015; 15:117. doi: 10.1186/s12866-015-0457-x PMID: 26048182; PubMed Central PMCID: PMC4458031.
38. Bucki R, Janmey PA. Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes. Antimicrobial agents and chemotherapy. 2006; 50(9):2932-40. doi: 10.1128/ AAC.00134-06 PMID: 16940084; PubMed Central PMCID: PMC1563552.
39. Kim KS, Kim YS, Han I, Kim MH, Jung MH, Park HK. Quantitative and qualitative analyses of the cell death process in Candida albicans treated by antifungal agents. PLoS One. 2011; 6(12):e28176. doi: 10.1371/journal.pone.0028176 PMID: 22174777; PubMed Central PMCID: PMCPMC3235109.
40. Tetz VV, Tetz GV. Effect of extracellular DNA destruction by DNase I on characteristics of forming biofilms. DNA Cell Biol. 2010; 29(8):399-405. doi: 10.1089/dna.2009.1011 PMID: 20491577.
41. Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol. 2013; 51(12):4167-72. doi: 10.1128/JCM.01998-13 PMID: 24108614; PubMed Central PMCID: PMCPMC3838046.
42. Leszczyñska K, Namiot A, Cruz K, Byfield FJ, Won E, Mendez G, et al. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections. J Appl Microbiol. 2011; 110(1):229-38. doi: 10.1111/j.1365-2672.2010.04874.x PMID: 20961363; PubMed Central PMCID: PMCPMC3386848.
43. García-Quintanilla M, Pulido MR, Moreno-Martínez P, Martín-Peña R, López-Rojas R, Pachón J, et al. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother. 2014; 58(5):2972-5. doi: 10.1128/AAC.02642-13 PMID: 24566189; PubMed Central PMCID: PMCPMC3993257.
44. Haisma EM, de Breij A, Chan H, van Dissel JT, Drijfhout JW, Hiemstra PS, et al. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents. Antimicrob Agents Chemother. 2014; 58(8):4411-9. doi: 10.1128/AAC.02554-14 PMID: 24841266; PubMed Central PMCID: PMCPMC4136056.
45. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, et al. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J. 2005; 388(Pt 2):689-95. doi: 10.1042/BJ20042099 PMID: 15707390; PubMed Central PMCID: PMCPMC1138977.
46. Tsai PW, Cheng YL, Hsieh WP, Lan CY. Responses of Candida albicans to the human antimicrobial peptide LL-37. J Microbiol. 2014; 52(7):581-9. doi: 10.1007/s12275-014-3630-2 PMID: 24879350.
47. Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, et al. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother. 2006; 58(5):950-9. doi: 10. 1093/jac/dkl382 PMID: 17023499.
48. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. The Journal of antimicrobial chemotherapy. 2008; 62(2):329-35. doi: 10.1093/jac/dkn176 PMID: 18456648; PubMed Central PMCID: PMC2734083.
49. Wong CS, Koh CL, Sam CK, Chen JW, Chong YM, Yin WF, et al. Degradation of bacterial quorum sensing signaling molecules by the microscopic yeast Trichosporon loubieri isolated from tropical wetland waters. Sensors (Basel). 2013; 13(10):12943-57. doi: 10.3390/s131012943 PMID: 24072030; PubMed Central PMCID: PMCPMC3859043.
50. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014; 20(7):698-705. doi: 10.1111/1469-0691.12440 PMID: 24188136.
51. Lyon GM, Karatela S, Sunay S, Adiri Y, Investigators CSS. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48(4):1270-5. doi: 10.1128/JCM. 02363-09 PMID: 20129963; PubMed Central PMCID: PMCPMC2849617.
52. Montagna MT, Lovero G, Coretti C, De Giglio O, Martinelli D, Bedini A, et al. In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates. J Med Microbiol. 2014; 63(Pt 12):1638-43. doi: 10.1099/jmm.0.075507-0 PMID: 25210203; PubMed Central PMCID: PMCPMC4250836.
53. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrob Agents Chemother. 2008; 52(3):1187-9. doi: 10.1128/AAC.01475-07 PMID: 18180345; PubMed Central PMCID: PMCPMC2258495.
54. Ordonez SR, Amarullah IH, Wubbolts RW, Veldhuizen EJ, Haagsman HP. Fungicidal mechanisms of cathelicidins LL-37 and CATH-2 revealed by live-cell imaging. Antimicrob Agents Chemother. 2014; 58 (4):2240-8. doi: 10.1128/AAC.01670-13 PMID: 24492359; PubMed Central PMCID: PMCPMC4023799.
55. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003; 55(1):27-55. doi: 10.1124/pr.55.1.2 PMID: 12615953.
56. Guembe M, Guinea J, Marcos-Zambrano LJ, Fernández-Cruz A, Peláez T, Muñoz P, et al. Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother. 2014; 58(9):5581-4. doi: 10.1128/AAC.02738-14 PMID: 24957821; PubMed Central PMCID: PMCPMC4135876.
57. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez-Ribot JL, et al. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia. 2010; 169(5):323-31. doi: 10.1007/s11046-009-9264-y PMID: 20012895; PubMed Central PMCID: PMCPMC3973130.
58. Jones EA, McGillivary G, Bakaletz LO. Extracellular DNA within a nontypeable Haemophilus influenzae-induced biofilm binds human beta defensin-3 and reduces its antimicrobial activity. J Innate Immun. 2013; 5(1):24-38. doi: 000339961 PMID: 22922323; PubMed Central PMCID: PMCPMC3640559. doi: 10.1159/000339961
59. Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol. 2009; 58(Pt 4):492-502. doi: 10.1099/jmm.0.005728-0 PMID: 19273646; PubMed Central PMCID: PMCPMC2677169.
60. Wnorowska U, Niemirowicz K, Myint M, Diamond SL, Wróblewska M, Savage PB, et al. Bactericidal activity of cathelicidin LL-37 and select cationic lipids against the hypervirulent P. aeruginosa strain LESB58. Antimicrob Agents Chemother. 2015; 59(7):3808-15. doi: 10.1128/AAC.00421-15 PMID: 25870055.
61. Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother. 2006; 57(2):260-5. Epub 2006/01/ 03. doi: dki460 [pii] doi: 10.1093/jac/dki460 PMID: 16387752.
62. Rapala-Kozik M, Bochenska O, Zawrotniak M, Wolak N, Trebacz G, Gogol M, et al. Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans. Infect Immun. 2015; 83(6):2518-30. doi: 10.1128/IAI. 00023-15 PMID: 25847962; Central PMCID: PMCPMC4432748.
63. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006; 1758(9):1408-25. doi: 10.1016/j.bbamem.2006. 03.030 PMID: 16716248.
64. Niemirowicz K, Surel U, Wilczewska AZ, Mystkowska J, Piktel E, Gu X, et al. Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles. J Nanobiotechnology. 2015; 13(1):32. doi: 10.1186/s12951-015-0093-5 PMID: 25929281.